Can early tumor response guide smarter cancer treatment?
NCT ID NCT07721103
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase II trial tests a personalized approach for people with locally advanced esophageal cancer. After initial chemoimmunotherapy, patients whose tumors shrink well go straight to surgery, while those with less response receive additional radiotherapy before surgery. The goal is to see if this response-guided strategy improves safety and outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of tislelizumab (PD-1 inhibitor), paclitaxel, cisplatin, and sequential radiotherapy
- What this could lead to
- If successful, this approach could offer a more personalized treatment plan for esophageal cancer, potentially improving surgical outcomes and survival.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. Adding radiotherapy also raises the risk of side effects like inflammation or tissue damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital
Tianjin, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
- Blood and tissue markers could forecast esophageal cancer return
- Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
- Could smarter surgery spare lymph nodes in esophageal cancer?
- Timing of local therapy may boost immunotherapy in Hard-to-Treat esophageal cancer